Novavax | NVAX - Equity Capital And Reserves


Novavax reported $-156.67M in Equity Capital and Reserves for its fiscal quarter ending in September of 2025.





Equity Capital And Reserves Change Date
Adma Biologics USD 431.19M 32.87M Sep/2025
Agenus USD -274.14M 80.46M Sep/2025
AstraZeneca USD 48.67B 2.78B Dec/2025
BioCryst Pharmaceuticals USD -387.89M 33.7M Sep/2025
Cassava Sciences USD 81.57M 6.4M Sep/2025
Geron USD 225.87M 22.83M Dec/2025
GlaxoSmithKline GBP 16.38B 229M Dec/2025
MannKind USD -51.02M 6.47M Dec/2025
Merck USD 51.85B 2.79B Sep/2025
Minerva Neurosciences USD -34.58M 2.47M Sep/2025
Moderna USD 8.65B 680M Dec/2025
Novartis USD 44.33B 2.28B Sep/2025
Novavax USD -156.67M 194.3M Sep/2025
Pfizer USD 92.8B 4.11B Sep/2025
Sanofi EUR 71.71B 1.55B Dec/2025
Sarepta Therapeutics USD 1.14B 179.5M Dec/2025
TG Therapeutics USD 648.02M 40.8M Dec/2025